Date: 2014-08-18
Type of information: Licensing agreement
Compound: E3710
Company: Eisai (Japan) Zeria Pharmaceutical (Japan)
Therapeutic area: Gastrointestinal diseases - Digestive diseases
Type agreement:
Action mechanism: E3710 is a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai as a successor to Pariet®. Compared to existing PPIs, E3710 potentially provides a stronger and a longer-lasting inhibitory effect on gastric acid secretion. E3710 shows promise as a best-in-class treatment which could shorten the treatment period and meet the needs of patients for whom existing PPIs are inadequate.
Disease: gastric acid secretion, gastritis, gastric ulcer
Details: * On August 18, 2014, Eisai and Zeria Pharmaceutical announced that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai. Based on this agreement, Eisai will grant Zeria the exclusive rights to develop and co-promote, and the non-exclusive right to manufacture, E3710 in Japan. In addition, Eisai will receive down payment and additional royalties from Zeria, and after marketing authorization has been successfully obtained, Eisai will pay Zeria a certain consideration. While Zeria will develop E3710 and work to obtain marketing authorization, the two companies will collaborate on marketing E3710 after launch. This license agreement will enhance the product pipeline of Zeria, who focuses on gastrointestinal diseases as a key franchise area, and maximize the value of Eisai\'s compound.
Financial terms:
Latest news:
